Walvax Biotechnology Co.
Walvax Biotech develops and sells vaccines and bio-medicine products in China, focusing on preventing infectious diseases.
Founded
2001Walvax Biotech develops and sells vaccines and bio-medicine products in China, focusing on preventing infectious diseases.
Founded in China, Walvax Biotechnology Co., Ltd. is dedicated to the research, development, production, and sale of bio-medicine products, primarily focusing on vaccines and blood products. The company's core mission is to prevent infectious diseases and improve public health through innovative biotechnological solutions. Walvax offers a range of vaccines, including the Group A and C meningococcal polysaccharide vaccine, targeting both children and adults to combat diseases caused by Neisseria meningitidis.
Walvax has garnered attention from notable figures in the biotech industry and has attracted significant investment to support its mission. The company has achieved key milestones in vaccine development and distribution within China, contributing to the broader public health landscape. Its impact is evident in the increased availability of preventive healthcare solutions, positioning Walvax as a crucial player in the fight against infectious diseases.
Companies similar to Walvax Biotechnology Co. include Sinovac Biotech, Chengdu Kanghua Biological Products Co., X-Vax Technology and Agilvax.
Walvax Biotechnology Co. was founded in 2001.
Walvax Biotechnology Co.'s headquarters is located in Kunming, Yunnan, CN.
Walvax Biotechnology Co.'s most recent funding round was for $72.8M (USD) in August 2014.
As of Aug 8, 2014, Walvax Biotechnology Co. has disclosed funding of $72.8M (USD). Undisclosed round amounts are excluded.
Walvax Biotechnology Co. has 2,249 employees as of Feb 12, 2024.
Agilvax
agilvax.com
